Compare Cassava Sciences Inc (FLNA) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kaltura Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Kaltura Inc trades at $1.32 (market cap $202.89M). The key difference: Kaltura Inc is far larger — about 5.1× Cassava Sciences Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kaltura Inc for 21 Days on average.
| FLNA | KLTR | |
|---|---|---|
Market Cap | $39.40M | $202.89M |
Volume | 759,018 | 214,400 |
Sector | Health | Technology |
52-Week High | $4.64 | $1.89 |
52-Week Low | $0.68 | $1.08 |
Typical Hold Time | 37 Days | 21 Days |
Enterprise Value | -$43.28M | $215.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Kaltura (KLTR) trades at $1.33, up 3.91% with recent earnings beats but negative profitability. Technical indicators show bearish momentum while fundamentals reveal improving margins despite net losses. The company is gaining industry recognition for AI-powered video platforms and secured major partnerships, though cash flow remains negative.
Investment outlook balances AI innovation potential against persistent financial challenges. While analyst sentiment leans positive with 44% buy ratings, high valuation multiples and negative ROE present significant risks. The stock offers speculative appeal for investors betting on AI-driven turnaround despite current unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
